Comparing real-time (RT-CGM) and intermittently scanned continuous glucose monitoring (IS-CGM)* in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicenter, randomised controlled trial[†]

Dexcom

Margaretha M Visser, Sara Charleer, Steffen Fieuws, et al. Published Online June 2, 2021 https://doi.org/10.1016/S0140-6736(21)00789-3

Background

People with type 1 diabetes (T1D) can continuously monitor their glucose levels on demand with IS-CGM, or in real time with RT-CGM.

However, it is unclear whether switching from IS-CGM to RT-CGM with alert functionality offers additional benefits.

Objective

Evaluate if use of switching from IS-CGM to RT-CGM with alert functionality improves glycemic outcomes and guality of life in adults with T1D.

Methods

Participants Eligibility



Adults >18 years

Participants with a diagnosis of T1D >6 mo

Using FreeStyle Libre IS-CGM system >6 mo

Participants are on intensified insulin therapy/ insulin pump therapy

A1C

Participants

246



The participant is willing to wear the glucose monitoring device >80% of the time



The participant is willing to download glucose monitoring data at regular intervals

Methods

Multicenter, double arm, open label, parallel group, randomized clinical trial.



Results



Time in Range

Difference in **Time in Range** (70-180 mg/dL) after 6 months between the control and intervention group.



A1C decreased in RT-CGM group compared to IS-CGM and this difference persisted up to 6 months.

Hypoglycemia

After switching to RT-CGM, time <54 mg/dL almost halved, resulting at month 6 in a mean difference of -0.35% (-0.61 to -0.10; p=0.0070)



-0.36% Mean difference at 6 months in A1C [95% CI, -0.48 to -0.24]; p<0.0001

Key takeaways



RT-CGM was superior to IS-CGM in allowing patients to achieve improved TIR[‡], A1C, and less time in hypoglycemia.



48% patients on RT-CGM reached an A1C <7% without severe hypoglycemia.



Results show that the participants had less fear of hypoglycemia with RT-CGM than IS-CGM use. Mean difference of -2.62% (p<0.0071).

For more information, visit provider.dexcom.com

*IS-CGM used in this trial was FreeStyle Libre 14 day system

† This clinical summary of the published article is interpreted by Dexcom

‡ Recommendations from the International Consensus on Time in Range, 2019 recommend individualized glycemic targets for high risk and/or older adults with a focus on reducing the percentage of time spent less than 70 md/dL and preventing excessive hyperglycemia.

1. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial Visser, Margaretha M et al. The Lancet, Volume 397, Issue 10291, 2275 - 2283

Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. @2021 Dexcom, Inc. All rights reserved.

LBL021700 Rev001